Neoadjuvant Befotertinib Combined Bevacizumab or Platinum-based Double Chemotherapy for Resectable Locally-advanced EGFR Mutation-positive Non-Small Cell Lung Cancer

Clinical trial NCT06755684 · RECRUITING

Trial details

NCT number: NCT06755684
Sponsor: Peng Zhang
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

EGFR Non-Small Cell Lung Cancer Locally Advanced Non-Small Cell Lung Cancer Pemetrexed Carboplatin Bevacizumab Antineoplastic Agents Tyrosine Kinase Inhibitor

Start date: 2024-11-07
Primary completion: 2025-12-31
Enrollment: 60

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.